Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Other financing activities (2023 - 2025)

Compass Therapeutics' Other financing activities history spans 3 years, with the latest figure at $8.6 million for Q3 2025.

  • For Q3 2025, Other financing activities rose 431800.0% year-over-year to $8.6 million; the TTM value through Dec 2025 reached $8.6 million, up 1490.79%, while the annual FY2025 figure was $8.6 million, 1490.79% up from the prior year.
  • Other financing activities for Q3 2025 was $8.6 million at Compass Therapeutics, up from $815000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $8.6 million in Q3 2025 and bottomed at -$815000.0 in Q1 2025.
  • The 3-year median for Other financing activities is $500.0 (2023), against an average of $1.1 million.
  • The largest YoY upside for Other financing activities was 431800.0% in 2025 against a maximum downside of 499.26% in 2025.
  • A 3-year view of Other financing activities shows it stood at -$1000.0 in 2023, then plummeted by 100.0% to -$2000.0 in 2024, then surged by 432000.0% to $8.6 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Other financing activities are $8.6 million (Q3 2025), $815000.0 (Q2 2025), and -$815000.0 (Q1 2025).